ESSA Pharma Inc logo

EPIX - ESSA Pharma Inc Share Price

$6.18 0.0  0.5%

Last Trade - 10/07/20

Sector
Healthcare
Size
Small Cap
Market Cap £102.0m
Enterprise Value £70.5m
Revenue £n/a
Position in Universe 3998th / 6339
Bullish
Bearish
Unlock EPIX Revenue
Momentum
Relative Strength (%)
1m +13.0%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -1.69%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Sep 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 March 2020, ESSA Pharma Inc revenues was not reported. Net loss increased from $6.1M to $14M. Higher net loss reflects Share-based payments increase from $470K to $3.7M (expense), Other R&D Expenses increase from $2.1M to $5.2M (expense), Share-based payments increase from $183K to $1.2M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.97 to -$0.67.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

EPIX Revenue Unlock EPIX Revenue

Net Income

EPIX Net Income Unlock EPIX Revenue

Normalised EPS

EPIX Normalised EPS Unlock EPIX Revenue

PE Ratio Range

EPIX PE Ratio Range Unlock EPIX Revenue

Dividend Yield Range

EPIX Dividend Yield Range Unlock EPIX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
EPIX EPS Forecasts Unlock EPIX Revenue
Profile Summary

ESSA Pharma, Inc. is a Canada-based pharmaceutical company focused on developing therapies for the treatment of castration-resistant prostate cancer (CRPC). It is developing EPI-7386 for the treatment of metastatic CRPC (mCRPC). It is also developing EPI-7386 combination therapy for mCRPC. In addition to this, the Company's pipeline also includes antien for triple negative androgen receptor (AR+) breast cancer. Its aniten compounds bind to the N-terminal domain of the androgen receptor (AR), inhibiting AR driven transcription and the AR signaling pathway in a manner which bypasses the drug resistance mechanisms associated with current anti-androgens.

Directors
Last Annual September 30th, 2019
Last Interim March 31st, 2020
Incorporated January 6, 2009
Public Since December 22, 2014
No. of Shareholders: n/a
No. of Employees: 11
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market (Dual Listing)
Shares in Issue 20,824,755
Free Float (0.0%)
Eligible for
ISAs
SIPPs
EPIX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for EPIX
Upcoming Events for EPIX
Frequently Asked Questions for ESSA Pharma Inc
What is the ESSA Pharma Inc share price?

As of 10/07/20, shares in ESSA Pharma Inc are trading at $6.18, giving the company a market capitalisation of £102.0m. This share price information is delayed by 15 minutes.

How has the ESSA Pharma Inc share price performed this year?

Shares in ESSA Pharma Inc are currently trading at $6.18 and the price has moved by 0.169k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the ESSA Pharma Inc price has moved by 0.157k% over the past year.

What are the analyst and broker recommendations for ESSA Pharma Inc?

There are no analysts currently covering ESSA Pharma Inc.

When will ESSA Pharma Inc next release its financial results?

ESSA Pharma Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the ESSA Pharma Inc dividend yield?

ESSA Pharma Inc does not currently pay a dividend.

Does ESSA Pharma Inc pay a dividend?

ESSA Pharma Inc does not currently pay a dividend.

When does ESSA Pharma Inc next pay dividends?

ESSA Pharma Inc does not currently pay a dividend.

How do I buy ESSA Pharma Inc shares?

To buy shares in ESSA Pharma Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of ESSA Pharma Inc?

Shares in ESSA Pharma Inc are currently trading at $6.18, giving the company a market capitalisation of £102.0m.

Where are ESSA Pharma Inc shares listed? Where are ESSA Pharma Inc shares listed?

Here are the trading details for ESSA Pharma Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: EPIX
What kind of share is ESSA Pharma Inc?

Based on an overall assessment of its quality, value and momentum, ESSA Pharma Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a ESSA Pharma Inc share price forecast 2020?

Shares in ESSA Pharma Inc are currently priced at $6.18. At that level they are trading at 44.69% discount to the analyst consensus target price of 0.00.

Analysts covering ESSA Pharma Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.9807961151 for the next financial year.

How can I tell whether the ESSA Pharma Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ESSA Pharma Inc. Over the past six months, the relative strength of its shares against the market has been 12.19%. At the current price of $6.18, shares in ESSA Pharma Inc are trading at 28.28% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the ESSA Pharma Inc PE Ratio?

We were not able to find PE ratio data for ESSA Pharma Inc.

Who are the key directors of ESSA Pharma Inc?

ESSA Pharma Inc's management team is headed by:

Richard Glickman - CHM
Marianne Sadar - CSO
Raymond Andersen - CTO
Gary Sollis - DRC
David Wood - CFO
Frank Perabo - OTH
Franklin Berger - DRC
David Parkinson - PRE
Scott Requadt - DRC
Peter Virsik - COO
Otello Stampacchia - DRC
Ari Brettman - DRC
Who are the major shareholders of ESSA Pharma Inc?

Here are the top five shareholders of ESSA Pharma Inc based on the size of their shareholding:

Clarus Ventures, LLC Venture Capital
Percentage owned: 16.2% (3.37m shares)
BVF Partners L.P. Hedge Fund
Percentage owned: 11.62% (2.42m shares)
Soleus Capital Management, L.P. Hedge Fund
Percentage owned: 9.99% (2.08m shares)
Eventide Asset Management, LLC Investment Advisor
Percentage owned: 9.65% (2.01m shares)
Omega Fund Management, LLC Investment Advisor
Percentage owned: 8.11% (1.69m shares)
Similar to EPIX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.